CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced that the company will participate in the following September investor conferences:
- Cantor Virtual Global Healthcare Conference, presentation at 8:00 a.m. ET on Wednesday, September 16
- Oppenheimer Virtual Fall Healthcare Life Sciences & MedTech Summit, presentation at 10:50 a.m. ET on Wednesday, September 23
Live webcasts can be accessed on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations. The webcast replays will be available for 90 days following each event.
About Magenta Therapeutics
Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.
Magenta is based in Cambridge, Mass. For more information, please visit www.magentatx. (Read more…)com.
Follow Magenta on Twitter: @magentatx.
Contacts
Lyndsey Scull, Director, Corporate Communications
202-213-7086
lscull@magentatx.com
Jill Bertotti, W2O Group
714-225-6726
jbertotti@w2ogroup.com